Join the 'Hyperkalemic Periodic Paralysis' group to help and get support from people like you.
Hyperkalemic Periodic Paralysis News
Posted 10 Aug 2015 by Drugs.com
HAWTHORNE, N.Y.--(BUSINESS WIRE)--Aug. 10, 2015-- Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that the U.S. Food and Drug Administration (FDA) has approved Keveyis (dichlorphenamide) 50 mg Tablets for the treatment of primary hyperkalemic and hypokalemic periodic paralysis, a group of rare hereditary disorders that cause episodes of muscle weakness or paralysis . Keveyis is the first medicine approved by the FDA for the treatment of primary periodic paralysis, which is estimated to affect approximately 5,000 people in the United States . “The approval of Keveyis demonstrates the importance of industry, scientific researchers, patient advocates and the FDA working together to identify and bring to market a treatment for primary periodic paralysis,” said Kal Sundaram, Chief Executive Officer of Taro. “Taro is proud of its commitment to this community, which has b ... Read more